CLSA has issued a research report reducing its earnings forecast for TIGERMED (03347) for the 2027 fiscal year by 7%, citing increased uncertainties in long-term investment returns. The firm continues to assign an "Outperform" rating to TIGERMED, while lowering the H-share target price from HK$68.2 to HK$59.9. The A-share target price for Hangzhou Tigermed Consulting Co.,Ltd. (300347) was also cut from RMB 81.9 to RMB 72. Although TIGERMED's order intake has shown improvement, market focus remains on the company's efficiency in converting orders into revenue and its ability to monetize investments. With short-term positive factors already reflected in the share price, the risk-reward profile is believed to have reached a balanced state.